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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERProsthetic Valve Thrombosis 1731
Grace Huang, Hartzell V. Schaff, Thoralf M. Sundt, Shahbudin H. Rahimtoola
Obstructive thrombosed prosthetic heart valve (OTPHV) is a serious complication of
heart valve replacement. Huang and colleagues have reviewed the literature to better
understand the clinical outcome of patients with OTPHV treated with thrombolytics or
surgery. Based on these ﬁndings and their clinical experience, they have subsequently
proposed a strategy for managing patients with OTPHV.CLINICAL RESEARCH HEART FAILUREPAR2 as a Regulator of Innate Immunity 1737
Alice Weithauser, Peter Bobbert, Silvio Antoniak, Andreas Böhm, Bernhard H. Rauch, Karin Klingel,
Konstantinos Savvatis, Heyo K. Kroemer, Carsten Tschope, Andrea Stroux, Heinz Zeichhardt,
Wolfgang Poller, Nigel Mackman, Heinz-Peter Schultheiss, Ursula Rauch
Weithauser and colleagues evaluate the role of protease-activated receptor-2 (PAR2) in
coxsackievirus B3 (CVB3)–induced myocarditis. To induce myocarditis, wild-type (wt) and
PAR2 knockout (ko) mice were infected with CVB3. Mice underwent hemodynamic
measurements, and wt and PAR2ko hearts and cardiac cells were analyzed for viral
replication and immune response. Results revealed that PAR2ko mice and cardiomyocytes
exhibited a reduced viral load and developed no myocarditis after infection with CVB3
compared with wt mice. Hearts and cardiac ﬁbroblast from PAR2ko mice expressed a higher
basal level of antiviral cytokine interferon-b (IFNb) compared with wt mice. The PAR2
expression in endomyocardial biopsies of patients with nonischemic cardiomyopathy
correlated positively with myocardial inﬂammation and negatively with IFNb expression and
left ventricular ejection fraction. This study shows that PAR2 negatively regulates the innate
immune response to CVB3 infection and contributes to myocardial dysfunction.
Editorial Comment: Jay W. Mason, p. 1746(continued on page A-34)
NOVEMBER 5, 2013 (continued) A-34CARDIAC IMAGINGPlaque Erosion and Calciﬁed Nodules by OCT 1748Haibo Jia, Farhad Abtahian, Aaron D. Aguirre, Stephen Lee, Stanley Chia, Harry Lowe,
Koji Kato, Taishi Yonetsu, Rocco Vergallo, Sining Hu, Jinwei Tian, Hang Lee, Seung-Jung Park,
Yang-Soo Jang, Owen C. Raffel, Kyoichi Mizuno, Shiro Uemura, Tomonori Itoh, Tsunekazu Kakuta,
So-Yeon Choi, Harold L. Dauerman, Abhiram Prasad, Catalin Toma, Iris McNulty, Shaosong Zhang,
Bo Yu, Valentine Fuster, Jagat Narula, Renu Virmani, Ik-Kyung Jang
The objective of this study was to characterize the morphological features of plaque erosion
and calciﬁed nodule in patients with acute coronary syndrome (ACS) by optical coherence
tomography (OCT). A total of 126 patients with ACS who had undergone pre-intervention
OCT were included. The culprit lesion was classiﬁed as plaque rupture (PR), erosion
(OCT-erosion), calciﬁed nodules (OCT-CN), or other using a new set of diagnostic criteria.
The incidence of PR, OCT-erosion, and OCT-CN was 43.7%, 31.0%, and 7.9%,
respectively. Compared with patients with PR, presentation with non–ST-segment elevation
acute coronary syndrome (NSTE-ACS) was more common in patients with OCT-erosion
(61% vs. 29%) and OCT-CN (100% vs. 29%). OCT-erosion had a lower frequency of
lipid plaque, a thicker ﬁbrous cap, and a smaller lipid arc than PR. Jia and colleagues conclude
that OCT is a promising modality for identifying OCT-erosion and OCT-CN in vivo.
OCT-erosion is a frequent ﬁnding in patients with ACS, especially in those with
NSTE-ACS and in younger patients. OCT-CN is the least common etiology for ACS and is
most common is older patients.
Editorial Comment: Stephen J. Nicholls, Rishi Puri, p. 1759HEART RHYTHM DISORDERSValue of CMR in Risk Stratiﬁcation of ARVD/C 1761
Anneline S. J. M. te Riele, Aditya Bhonsale, Cynthia A. James, Neda Rastegar, Brittney Murray,
Jeremy R. Burt, Crystal Tichnell, Srinivasa Madhavan, Daniel P. Judge, David A. Bluemke,
Stefan L. Zimmerman, Ihab R. Kamel, Hugh Calkins, Harikrishna Tandri
te Riele and colleagues evaluated the role of cardiac magnetic resonance (CMR) in
arrhythmic risk stratiﬁcation of arrhythmogenic right ventricular dysplasia/cardiomyopathy
(ARVD/C)-associated desmosomal mutation carriers without a history of sustained
ventricular arrhythmia. Overall, 42 (61%) patients presented with electrical abnormalities
based on their ECG and Holter monitor, of whom 20 (48%) patients had an abnormal
CMR. Only 1 (4%) of 27 patients without electrical abnormality at initial evaluation had an
abnormal CMR. Over a mean follow-up period, 11 (16%) patients experienced a sustained
ventricular arrhythmia, and all had both electrical abnormality (ECG and/or Holter) and
abnormal CMR. The results suggest that evaluation of cardiac structure and function using
CMR is probably not necessary in the absence of baseline electrical abnormality. Among
ARVD/C mutation carriers, the presence of both electrical and CMR abnormalities
identiﬁes a patient at high risk of events.
Editorial Comment: Bruce D. Lindsay, p. 1770(continued on page A-36)
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Cynthia James, Andrew D. Krahn, Daniel P. Judge, Hugh Calkins, Michael H. Gollob
Perrin and colleagues sought to determine whether exercise testing could expose a latent
electrical substrate of arrhythmogenic right ventricular cardiomyopathy (ARVC) in
asymptomatic gene carriers. Exercise-induced abnormalities during exercise treadmill testing
were compared in 30 asymptomatic ARVC gene carriers, 30 healthy cohorts, and 25 ARVC
patients with a history of sustained ventricular arrhythmias or cardiac arrest. Depolarization
abnormalities (epsilon waves, premature ventricular contractions, and new QRS terminal
activation duration >55 ms) were found to develop more frequently in asymptomatic gene
carriers compared with healthy controls. The same abnormalities were also found to be
frequent in symptomatic ARVC patients. The authors conclude that exercise testing exposes
a latent electrical substrate in asymptomatic ARVC gene carriers that is shared by ARVC
patients with a history of ventricular arrhythmias. Exercise testing may be useful in guiding
the management of asymptomatic ARVC gene carriers.HYPERTENSIONCentral BP for Diagnosing Hypertension 1780
Hao-Min Cheng, Shao-Yuan Chuang, Shih-Hsien Sung, Wen-Chung Yu, Alan Pearson,
Edward G. Lakatta, Wen-Harn Pan, Chen-Huan Chen
The objective of this study was to derive and subsequently validate outcome-driven thresholds
of central blood pressure (CBP) for diagnosing hypertension. In a derivation cohort
(n ¼ 1,272, median follow-up 15 years), the diagnostic thresholds for CBP were determined.
Subsequently, to evaluate the discriminatory power in predicting cardiovascular outcomes, the
derived thresholds were tested in a validation cohort (n ¼ 2,501, median follow-up 10 years).
Systolic/diastolic thresholds of CBP were 110/80 mm Hg for optimal blood pressure (BP)
and 130/90 mm Hg for hypertension. Compared with optimal BP, the risk of cardiovascular
mortality increased signiﬁcantly in subjects with hypertension (hazard ratio: 3.08). The
results show that a CBP of 130/90 mm Hg was the cutoff limit for normality and was
characterized by a greater discriminatory power for long-term events in the validation cohort.
Editorial Comment: Michael A. Weber, Raymond R. Townsend, p. 1788(continued on page A-38)
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Suzanne V. Arnold, John A. Spertus, Frederick A. Masoudi, Stacie L. Daugherty, Thomas M. Maddox,
Yan Li, John A. Dodson, Paul S. Chan
Arnold and colleagues evaluated whether patients receive optimal dosing of secondary
prevention medications at the time of and following discharge after acute myocardial
infarction (AMI). Treatment doses of beta-blockers, statins, and angiotensin-converting
enzyme inhibitors (ACE)/angiotensin II receptor blockers (ARBs) at discharge and 12
months after AMI among 6,748 patients were evaluated. They showed that most eligible
patients (>87%) were prescribed some dose of each medication at discharge, although only 1
in 3 patients were at goal dose. At 12 months, the goal doses of beta-blockers, statins, and
ACE/ARBs were achieved only in 12%, 26%, and 32% of patients, respectively. Multivariate
analysis showed that prescription of goal dose at discharge was strongly associated with being
at goal dose at follow-up. The authors conclude that although nearly all AMI patients are
discharged on appropriate secondary preventive medications, dose increases occur
infrequently, and most patients are prescribed doses below those with proven efﬁcacy in
clinical trials.
Editorial Comment: Christopher P. Cannon, p. 1802PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCHDetecting Lipids in Plaques Using Ultrasound 1804
Ahmed M. Mahmoud, Debaditya Dutta, Linda Lavery, Douglas N. Stephens,
Flordeliza S. Villanueva, Kang Kim
This study evaluates the feasibility of in vivo detection of lipids in atherosclerotic plaque
by ultrasound (US) thermal strain imaging (TSI). The US heating-imaging pulse sequences
and transducers were designed and integrated into commercial US scanners for US-TSI.
Segments from injured atherosclerotic and uninjured nonatherosclerotic common femoral
artery (CFA) of rabbits were scanned. The results revealed that lipid-rich atherosclerotic
lesions exhibited distinct positive TSI compared with that in nonatherosclerotic controls. The
US-TSI enabled serial monitoring of lipids during atherosclerosis development, and the
morphological and compositional information detected correlated with histology. Mahmoud
and colleagues conclude that US-TSI successfully detected and longitudinally monitored
lipid progression in atherosclerotic CFA.
